Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review

Display Omitted

Gespeichert in:

Autor*in:	Hirte, Hal [verfasserIn] Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Neoadjuvant therapy Cytoreductive surgery PD-L1 Systematic review Intraperitoneal therapy Adjuvant therapy Ovarian cancer Bevacizumab

Übergeordnetes Werk:	Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.]
Übergeordnetes Werk:	volume:162 ; year:2021 ; pages:0

Links:	Volltext

DOI / URN:	10.1016/j.critrevonc.2021.103324

Katalog-ID:	ELV054371694

Internformat


LEADER	01000caa a22002652 4500
001	ELV054371694
003	DE-627
005	20230624210834.0
007	cr uuu---uuuuu
008	210910s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.critrevonc.2021.103324 \|2 doi
028	5	2	\|a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica
035			\|a (DE-627)ELV054371694
035			\|a (ELSEVIER)S1040-8428(21)00112-8
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a 44.52 \|2 bkl
100	1		\|a Hirte, Hal \|e verfasserin \|4 aut
245	1	0	\|a Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
264		1	\|c 2021
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a Display Omitted
650		7	\|a Neoadjuvant therapy \|2 Elsevier
650		7	\|a Cytoreductive surgery \|2 Elsevier
650		7	\|a PD-L1 \|2 Elsevier
650		7	\|a Systematic review \|2 Elsevier
650		7	\|a Intraperitoneal therapy \|2 Elsevier
650		7	\|a Adjuvant therapy \|2 Elsevier
650		7	\|a Ovarian cancer \|2 Elsevier
650		7	\|a Bevacizumab \|2 Elsevier
700	1		\|a Poon, Raymond \|4 oth
700	1		\|a Yao, Xiaomei \|4 oth
700	1		\|a May, Taymaa \|4 oth
700	1		\|a Ethier, Josee-Lyne \|4 oth
700	1		\|a Petz, Lauri \|4 oth
700	1		\|a Speakman, Jane \|4 oth
700	1		\|a Elit, Laurie \|4 oth
773	0	8	\|i Enthalten in \|n Elsevier Science \|a Dettori, D. ELSEVIER \|t miR-214 in stroma cells and tumor progression \|d 2016 \|g Amsterdam [u.a.] \|w (DE-627)ELV019637179
773	1	8	\|g volume:162 \|g year:2021 \|g pages:0
856	4	0	\|u https://doi.org/10.1016/j.critrevonc.2021.103324 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_70
912			\|a GBV_ILN_100
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2016
912			\|a GBV_ILN_2048
936	b	k	\|a 44.52 \|j Therapie \|x Medizin \|q VZ
951			\|a AR
952			\|d 162 \|j 2021 \|h 0

Indexfelder

author_variant	h h hh
matchkey_str	hirtehalpoonraymondyaoxiaomeimaytaymaaet:2021----:eajvnadduatytmchrpfreldansdtgiieihlaoayalpatbopiaye
hierarchy_sort_str	2021
bklnumber	44.52
publishDate	2021
allfields	10.1016/j.critrevonc.2021.103324 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica (DE-627)ELV054371694 (ELSEVIER)S1040-8428(21)00112-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Hirte, Hal verfasserin aut Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Elsevier Poon, Raymond oth Yao, Xiaomei oth May, Taymaa oth Ethier, Josee-Lyne oth Petz, Lauri oth Speakman, Jane oth Elit, Laurie oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:162 year:2021 pages:0 https://doi.org/10.1016/j.critrevonc.2021.103324 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 162 2021 0
spelling	10.1016/j.critrevonc.2021.103324 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica (DE-627)ELV054371694 (ELSEVIER)S1040-8428(21)00112-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Hirte, Hal verfasserin aut Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Elsevier Poon, Raymond oth Yao, Xiaomei oth May, Taymaa oth Ethier, Josee-Lyne oth Petz, Lauri oth Speakman, Jane oth Elit, Laurie oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:162 year:2021 pages:0 https://doi.org/10.1016/j.critrevonc.2021.103324 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 162 2021 0
allfields_unstemmed	10.1016/j.critrevonc.2021.103324 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica (DE-627)ELV054371694 (ELSEVIER)S1040-8428(21)00112-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Hirte, Hal verfasserin aut Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Elsevier Poon, Raymond oth Yao, Xiaomei oth May, Taymaa oth Ethier, Josee-Lyne oth Petz, Lauri oth Speakman, Jane oth Elit, Laurie oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:162 year:2021 pages:0 https://doi.org/10.1016/j.critrevonc.2021.103324 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 162 2021 0
allfieldsGer	10.1016/j.critrevonc.2021.103324 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica (DE-627)ELV054371694 (ELSEVIER)S1040-8428(21)00112-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Hirte, Hal verfasserin aut Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Elsevier Poon, Raymond oth Yao, Xiaomei oth May, Taymaa oth Ethier, Josee-Lyne oth Petz, Lauri oth Speakman, Jane oth Elit, Laurie oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:162 year:2021 pages:0 https://doi.org/10.1016/j.critrevonc.2021.103324 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 162 2021 0
allfieldsSound	10.1016/j.critrevonc.2021.103324 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica (DE-627)ELV054371694 (ELSEVIER)S1040-8428(21)00112-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Hirte, Hal verfasserin aut Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Elsevier Poon, Raymond oth Yao, Xiaomei oth May, Taymaa oth Ethier, Josee-Lyne oth Petz, Lauri oth Speakman, Jane oth Elit, Laurie oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:162 year:2021 pages:0 https://doi.org/10.1016/j.critrevonc.2021.103324 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 162 2021 0
language	English
source	Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:162 year:2021 pages:0
sourceStr	Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:162 year:2021 pages:0
format_phy_str_mv	Article
bklname	Therapie
institution	findex.gbv.de
topic_facet	Neoadjuvant therapy Cytoreductive surgery PD-L1 Systematic review Intraperitoneal therapy Adjuvant therapy Ovarian cancer Bevacizumab
dewey-raw	610
isfreeaccess_bool	false
container_title	miR-214 in stroma cells and tumor progression
authorswithroles_txt_mv	Hirte, Hal @@aut@@ Poon, Raymond @@oth@@ Yao, Xiaomei @@oth@@ May, Taymaa @@oth@@ Ethier, Josee-Lyne @@oth@@ Petz, Lauri @@oth@@ Speakman, Jane @@oth@@ Elit, Laurie @@oth@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	ELV019637179
dewey-sort	3610
id	ELV054371694
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054371694</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624210834.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2021.103324</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054371694</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(21)00112-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hirte, Hal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Display Omitted</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neoadjuvant therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytoreductive surgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-L1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Systematic review</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intraperitoneal therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adjuvant therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ovarian cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bevacizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Poon, Raymond</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yao, Xiaomei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">May, Taymaa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ethier, Josee-Lyne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Petz, Lauri</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Speakman, Jane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elit, Laurie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:162</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2021.103324</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">162</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
author	Hirte, Hal
spellingShingle	Hirte, Hal ddc 610 bkl 44.52 Elsevier Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
authorStr	Hirte, Hal
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV019637179
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 VZ 44.52 bkl Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab Elsevier
topic	ddc 610 bkl 44.52 Elsevier Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab
topic_unstemmed	ddc 610 bkl 44.52 Elsevier Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab
topic_browse	ddc 610 bkl 44.52 Elsevier Neoadjuvant therapy Elsevier Cytoreductive surgery Elsevier PD-L1 Elsevier Systematic review Elsevier Intraperitoneal therapy Elsevier Adjuvant therapy Elsevier Ovarian cancer Elsevier Bevacizumab
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	r p rp x y xy t m tm j l e jle l p lp j s js l e le
hierarchy_parent_title	miR-214 in stroma cells and tumor progression
hierarchy_parent_id	ELV019637179
dewey-tens	610 - Medicine & health
hierarchy_top_title	miR-214 in stroma cells and tumor progression
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV019637179
title	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
ctrlnum	(DE-627)ELV054371694 (ELSEVIER)S1040-8428(21)00112-8
title_full	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
author_sort	Hirte, Hal
journal	miR-214 in stroma cells and tumor progression
journalStr	miR-214 in stroma cells and tumor progression
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2021
contenttype_str_mv	zzz
container_start_page	0
author_browse	Hirte, Hal
container_volume	162
class	610 VZ 44.52 bkl
format_se	Elektronische Aufsätze
author-letter	Hirte, Hal
doi_str_mv	10.1016/j.critrevonc.2021.103324
dewey-full	610
title_sort	neoadjuvant and adjuvant systemic therapy for newly diagnosed stage ii- iv epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a systematic review
title_auth	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
abstract	Display Omitted
abstractGer	Display Omitted
abstract_unstemmed	Display Omitted
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048
title_short	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
url	https://doi.org/10.1016/j.critrevonc.2021.103324
remote_bool	true
author2	Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie
author2Str	Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie
ppnlink	ELV019637179
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth oth oth
doi_str	10.1016/j.critrevonc.2021.103324
up_date	2024-07-06T21:32:54.967Z
_version_	1803866944273645568
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054371694</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624210834.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2021.103324</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001419.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054371694</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(21)00112-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hirte, Hal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Display Omitted</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neoadjuvant therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytoreductive surgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-L1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Systematic review</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intraperitoneal therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adjuvant therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ovarian cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bevacizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Poon, Raymond</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yao, Xiaomei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">May, Taymaa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ethier, Josee-Lyne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Petz, Lauri</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Speakman, Jane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elit, Laurie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:162</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2021.103324</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">162</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
score	7.3985004

Nicht das Richtige dabei?

Schreiben Sie uns!

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?